Aurinia Pharmaceuticals Inc. (FRA:IKAP)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.00B +49.5% |
| Revenue (ttm) | 272.66M +19.8% |
| Net Income | 274.94M +418.0% |
| EPS | 2.06 +447.9% |
| Shares Out | n/a |
| PE Ratio | 7.29 |
| Forward PE | 20.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 15.14 |
| Previous Close | 14.82 |
| Day's Range | 14.99 - 15.14 |
| 52-Week Range | 9.81 - 16.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Can... [Read more]
Financial Performance
In 2025, Aurinia Pharmaceuticals's revenue was $283.06 million, an increase of 20.38% compared to the previous year's $235.13 million. Earnings were $287.20 million, an increase of 4893.08%.
Financial numbers in USD Financial StatementsNews
Aurinia Pharmaceuticals price target raised to $18 from $17 at TD Cowen
TD Cowen raised the firm’s price target on Aurinia Pharmaceuticals (AUPH) to $18 from $17 and keeps a Buy rating on the shares. The firm updated its model following Q3…
LB Pharmaceuticals appoints Joseph Miller as CFO
LB Pharmaceuticals (LBRX) announced the appointment of Joseph Miller as CFO. Prior to joining LB Pharmaceuticals, Miller served as CFO of Aurinia Pharmaceuticals (AUPH).
Aurinia settles patent litigation with Teva
Aurinia Pharmaceuticals (AUPH) announced that it and its subsidiary, Aurinia Pharma U.S., Inc., have entered into a settlement agreement with Teva Pharmaceuticals Inc. (TEVA) to resolve patent infring...
Aurinia Settles Patent Litigation with Teva
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
Aurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital
RBC Capital analyst Douglas Miehm raised the firm’s price target on Aurinia Pharmaceuticals (AUPH) to $16 from $15 and keeps a Sector Perform rating on the shares. Published first on…
Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M
Aurinia reiterates its guidance for 2026 total revenue of $315M-$325M, up 11% to 15% compared to 2025, and 2026 net product sales of $305M-$315M, up 12% to 16% compared to…
Aurinia Pharmaceuticals reports Q2 EPS 28c, consensus 24c
Reports Q2 revenue $83.2M, consensus $80.48M.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.
Aurinia Pharmaceuticals Earnings release: Q2 2026
Aurinia Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Aurinia Pharmaceuticals Quarterly report: Q2 2026
Aurinia Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Aurinia Pharmaceuticals announces initiation of PRESERVE study
Aurinia Pharmaceuticals (AUPH) announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with ...
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination ...
Aurinia presents new analysis of AURORA 1 Phase 3 study of Lupkynis
Aurinia Pharmaceuticals (AUPH) announced that a new analysis of the AURORA 1 Phase 3 study of Lupkynis in the treatment of lupus nephritis is being presented at the European Alliance…
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death.
Aurinia Pharmaceuticals up 4% in pre-market after insider transactions
Last night, the company stated: “Tang Capital Management announces that on June 2, 2026, it acquired 206,005 common shares of Aurinia Pharmaceuticals (AUPH) at a price of US $15.28 per…
Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
Reports Q1 revenue $77.7M, consensus $76.98M. “Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases,” stated Kevin Tang, Chief...
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.
Aurinia Pharmaceuticals Earnings release: Q1 2026
Aurinia Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Aurinia Pharmaceuticals Quarterly report: Q1 2026
Aurinia Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Aurinia Pharmaceuticals Proxy statement: Proxy filing
Aurinia Pharmaceuticals filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies
After Aurinia Pharmaceuticals (AUPH) announced an agreement to acquire Kezar Life Sciences (KZR) for $6.955 in cash per share plus one non-transferable contingent value right, Jefferies said the deal ...
Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
Aurinia Pharmaceuticals (AUPH) has entered into a definitive merger agreement to acquire Kezar Life Sciences (KZR) for $6.955 in cash per share of Kezar common stock, plus one non-transferable conting...
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value ...
MKT Capital ‘applauds’ Aurinia’s management transition
MKT Capital, a long-term shareholder of Aurinia Pharmaceuticals (AUPH), issued a statement in response to the company’s announcement that Kevin Tang has been appointed CEO. Antoine Khalife, Founder of...
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition
CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” o...